Clinical Trials Browser

Phase 3 × Not yet recruiting × Nasopharyngeal Neoplasms × Clear all

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 3 Not yet recruiting

Nasopharyngeal Neoplasms